Boston Scientific (BSX) Q4 FY24 earnings call

Boston Scientific delivered an exceptional Q4 and full-year FY24, driven by strong organic growth across its diversified portfolio and significant uptake of FARAPULSE. The company exceeded its financial goals, demonstrating robust execution and innovation. Management anticipates continued differentiated performance in FY25, balancing operating margin expansion with strategic investments to fuel long-term growth and maintain market leadership.